Tango Therapeutics, Inc.
TNGX
$1.28
-$0.095-6.91%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 15.18% | 15.67% | 26.16% | 49.72% | 46.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.18% | 15.67% | 26.16% | 49.72% | 46.93% |
| Cost of Revenue | 24.93% | 25.12% | 18.04% | 14.24% | 8.77% |
| Gross Profit | -29.46% | -29.82% | -14.65% | -3.83% | 2.93% |
| SG&A Expenses | 23.22% | 21.81% | 19.82% | 22.15% | 18.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.53% | 24.35% | 18.44% | 15.99% | 10.86% |
| Operating Income | -27.52% | -27.32% | -16.16% | -8.76% | -2.79% |
| Income Before Tax | -28.03% | -23.31% | -9.00% | -0.50% | 6.02% |
| Income Tax Expenses | 55.22% | 49.28% | 52.17% | 222.22% | 148.15% |
| Earnings from Continuing Operations | -28.07% | -23.34% | -9.05% | -0.61% | 5.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.07% | -23.34% | -9.05% | -0.61% | 5.95% |
| EBIT | -27.52% | -27.32% | -16.16% | -8.76% | -2.79% |
| EBITDA | -28.04% | -27.80% | -16.19% | -8.40% | -2.10% |
| EPS Basic | -9.47% | -5.39% | 6.65% | 10.36% | 10.84% |
| Normalized Basic EPS | -7.34% | -4.65% | 7.37% | 11.14% | 11.61% |
| EPS Diluted | -9.47% | -5.39% | 6.65% | 10.36% | 10.84% |
| Normalized Diluted EPS | -7.34% | -4.65% | 7.37% | 11.14% | 11.61% |
| Average Basic Shares Outstanding | 16.96% | 16.78% | 16.55% | 11.05% | 5.53% |
| Average Diluted Shares Outstanding | 16.96% | 16.78% | 16.55% | 11.05% | 5.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |